Makers Laboratories Limited
BSE: MAKERSL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Makers Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Makers Laboratories Limited is an Indian pharmaceutical company that manufactures and markets a diverse range of generic and branded formulations. Its portfolio spans key therapeutic segments including anti-diabetics, anti-malarials, cardiovascular drugs, antibiotics, and ophthalmic preparations.
Business Model
The company generates revenue through the production and distribution of pharmaceutical products across India, leveraging a network of stockists and medical representatives. It benefits from technical expertise and operational synergies derived from its association with the promoters of Ipca Laboratories.
Management Commentary
Management focuses on providing affordable healthcare solutions while expanding the company's reach across both acute and chronic therapy areas in the domestic market.
Growth Outlook
Growth is driven by the expansion of the company's product reach in acute and chronic therapy segments throughout India. The firm continues to leverage its manufacturing capabilities and industry synergies to maintain its market presence.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining Good Manufacturing Practices and adhering to evolving pharmaceutical regulations in India.
- Market Competition. The Indian pharmaceutical sector is highly fragmented and competitive, which may exert pressure on pricing and profit margins.
- Price Controls. Government-mandated price caps on essential medicines can significantly impact the revenue and profitability of pharmaceutical manufacturers.
- Supply Chain Dependency. Reliance on external suppliers for active pharmaceutical ingredients and raw materials poses a risk to consistent production schedules.
Start your research today
Unlock AI insights, financials, peers and live data on Makers Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹141 Cr
TTM · consolidated
NET PROFIT
₹8 Cr
TTM · consolidated
EPS
₹4.38
TTM · consolidated
RETURN ON EQUITY
11.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
4.4%
TTM · standalone
P/E
34.2x
Q4 FY26 · consolidated
EV/EBITDA
5.8x
Q4 FY26 · consolidated
EBITDA MARGIN
11.7%
TTM · consolidated
NET PROFIT MARGIN
10.0%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.1x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Makers Laboratories LimitedMAKERSL | ₹117 Cr | 45.37 | 7.41 | 16.4% | 11.7% | 11.1% | 4.4% | +33.4% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Makers Laboratories Limited
BSE: MAKERSL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Makers Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Makers Laboratories Limited is an Indian pharmaceutical company that manufactures and markets a diverse range of generic and branded formulations. Its portfolio spans key therapeutic segments including anti-diabetics, anti-malarials, cardiovascular drugs, antibiotics, and ophthalmic preparations.
Business Model
The company generates revenue through the production and distribution of pharmaceutical products across India, leveraging a network of stockists and medical representatives. It benefits from technical expertise and operational synergies derived from its association with the promoters of Ipca Laboratories.
Management Commentary
Management focuses on providing affordable healthcare solutions while expanding the company's reach across both acute and chronic therapy areas in the domestic market.
Growth Outlook
Growth is driven by the expansion of the company's product reach in acute and chronic therapy segments throughout India. The firm continues to leverage its manufacturing capabilities and industry synergies to maintain its market presence.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining Good Manufacturing Practices and adhering to evolving pharmaceutical regulations in India.
- Market Competition. The Indian pharmaceutical sector is highly fragmented and competitive, which may exert pressure on pricing and profit margins.
- Price Controls. Government-mandated price caps on essential medicines can significantly impact the revenue and profitability of pharmaceutical manufacturers.
- Supply Chain Dependency. Reliance on external suppliers for active pharmaceutical ingredients and raw materials poses a risk to consistent production schedules.
Start your research today
Unlock AI insights, financials, peers and live data on Makers Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹141 Cr
TTM · consolidated
NET PROFIT
₹8 Cr
TTM · consolidated
EPS
₹4.38
TTM · consolidated
RETURN ON EQUITY
11.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
4.4%
TTM · standalone
P/E
34.2x
Q4 FY26 · consolidated
EV/EBITDA
5.8x
Q4 FY26 · consolidated
EBITDA MARGIN
11.7%
TTM · consolidated
NET PROFIT MARGIN
10.0%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.1x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26